Fulgent Genetics has a low Price/Book ratio and promising drug candidates. Key trial results are expected in May 2025. Read ...

Quantum-Si's next-gen protein sequencing tech and growth partnerships show promise, but high costs, financial risks, and ...

Marketable securities include short-term investments that can be readily sold, while accounts receivable represent money owed to the company that is expected to be collected soon. For an example ...

The third of four looks at how specific accounting firm niches are being impacted — for good and ill — by artificial ...

On March 12, 2025, the staff of the Division of Corporation Finance at the Securities and Exchange Commission (SEC) issued a no-action letter ...

PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...

Team Buffett sold about 67% of its stake in Apple Inc. AAPL in 2024, selling most of it in the first three quarters of the ...

Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Q4 2024 Earnings Call Transcript March 6, 2025 Atea Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.4 EPS, expectations were $-0.35. Operator: Good afternoon, everybody, and ...

Q4 2024 Earnings Call Transcript March 13, 2025 Operator: Good day, and welcome to CPS Technologies Fourth Quarter and Year-End 2024 Earnings Call. [Operator Instructions]. It is now my pleasure to ...